Nondestructive, single tablet analysis using the NIRS XDS RapidContent Analyzer

Importance of the Topic

Near-infrared spectroscopy (NIRS) offers a rapid, non-destructive approach for analyzing solid dosage forms, streamlining quality control workflows compared to traditional liquid chromatography. Its minimal sample preparation, absence of solvents, and suitability for in-line or at-line monitoring make NIRS especially valuable in pharmaceutical manufacturing.

Objectives and Study Overview

This application note evaluates the performance of the NIRS XDS RapidContent Analyzer for single-tablet screening of procainamide HCl formulations (500 mg and 750 mg). The study aims to develop and validate a calibration model that correlates NIR spectra with active-ingredient content, comparing results against a reference HPLC method.

Methodology and Instrumentation

A NIRS XDS RapidContent Analyzer was operated in reflectance mode over 1100–2500 nm. Each tablet was centered in the sample port and scanned in under 30 seconds without any preparation or solvent use. Spectral preprocessing included conversion to second derivative spectra to minimize scattering effects. Calibration sets were built by scanning 100 tablets per lot and pairing NIR spectra with HPLC assay data for the most spectrally divergent samples.

Key Results and Discussion

The second derivative spectra revealed distinct absorption features attributable to procainamide HCl, particularly around 1368 nm. A univariate calibration model at this wavelength yielded:

• Correlation coefficient: –0.84
• Standard error of calibration (SEC): 1.7 mg
• Standard error of prediction (SEP) on a validation lot: 1.4 mg
• Maximum relative residual error: 0.53% (calibration) and 0.43% (validation)

These metrics demonstrate strong agreement between NIRS and HPLC results. An additional evaluation on 500 mg tablets confirmed the model’s robustness, which improves further as more diverse samples are incorporated.

Benefits and Practical Applications

NIRS enables rapid (< 30 s), solvent-free assay of tablets without altering the product, reducing laboratory preparation time and consumable costs. Its portability allows deployment directly on production lines or in conventional QC labs, eliminating sample transport and enabling real-time release testing.

Future Trends and Opportunities

Advancements in chemometric algorithms and expanded spectral libraries will enhance model robustness across broader formulation ranges. Integration of NIRS into process analytical technology (PAT) frameworks holds promise for continuous monitoring and adaptive control in pharmaceutical manufacturing. Emerging handheld and OEM NIRS modules may extend applications to other dosage forms and raw material screening.

Conclusion

The NIRS XDS RapidContent Analyzer demonstrates a reliable, rapid, and non-destructive method for tablet assay, offering a practical alternative to HPLC for uniformity and content testing. Implementation of this technique can reduce analysis time and cost, while supporting in-process monitoring and on-site quality assurance.